Astria Therapeutics (ATXS)

• Market cap: $686M
• 1 day: 0.41%
• 5 days: 2.61%
• 1 month: 62.58%
• 3 months: 90.19%
• 6 months: 164.29%
• Year to date: 36.12%
• 1 year: 3.91%
• 5 years: -65.51%
• 10 years: -97.1%
• Sector: Healthcare
• Industry: Biotechnology

About: Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.

Employees: 78